The Pharma Data

AUGUST 15, 2021

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Most train the immune system to recognize the RBD, a peptide that is the portion of the SARS-CoV-2 spike protein that binds to the ACE-2 receptor on host cell surfaces. bioRxiv [Preprint].

Protein 52

Protein Vaccination Vaccine Antibody 52

Pharmaceutical Technology

MARCH 2, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is an engineered B-cell modulator. The company offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics.

Protein 100

Protein Engineer Clinical Trials Clinical Trials 100

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. Chief Executive Officer at Arvinas.

Protein 52

Protein Development HR Hormones 52

XTalks

SEPTEMBER 21, 2023

“HIV continues to be a major global public health challenge with no approved vaccines despite decades of research efforts,” said Carey Hwang, Vir’s Senior Vice President, Clinical Research, Head of Chronic Infection, in the company’s press release. mRNA, 2) BG505 MD39.3 gp151 mRNA and 3) BG505 MD39.3 gp151 CD4KO mRNA.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Pharmaceutical Technology

NOVEMBER 29, 2022

For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours. These viruses are engineered genetically for killing cancer. GBMs are called “cold” tumours as they lack helpful immune cells.

Development 130

Development Research Antibody Engineer 130

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Scienmag

MAY 27, 2021

Credit: Chris Pudney, University of Bath A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability – […].

Protein 52

Protein Scientist Medicine Development 52

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is developed based on protein engineering platform. It acts by targeting TGF-beta 1 and 3.

Production 100

Production Vaccination Vaccine Engineer 100

Drug Discovery World

OCTOBER 20, 2023

Its proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. Through the purchase, Thermo Fisher will also gain a library of more than 5,300 validated protein biomarker targets. Olink specialises in solutions for proteomics discovery and development.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Drug Discovery World

OCTOBER 24, 2023

A BioIndustry Association (BIA) report lists the widespread adoption of artificial intelligence (AI) and machine learning (ML), the advancement of gene editing technologies, the power of engineering biology, and a growing interest from major pharmaceutical players as key trends driving the sector.

Gene Editing 52

Gene Editing Engineer Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MARCH 23, 2023

Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics. Adcetris is currently active in multiple clinical trials, including the ECHELON-3 Phase lll study for patients with relapsed or refractory diffuse large B-cell lymphoma.

Licensing 147

Licensing Licensing Sales Trials 147

Scienmag

APRIL 12, 2021

Credit: POSTECH Blood vessels deliver nutrients and oxygen to each organ in our body. They are difficult to completely restore to their original conditions once damaged by myocardial infarction or severe ischemic diseases. This is because various angiogenic growth factors must be applied sequentially in order to restore the vascular structure.

Protein 83

Protein Research Clinical Trials Clinical Trials 83

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. It also bodes well for improving clinical trial success rates. What, then, is the solution?

Development 135

Development Research Drugs Clinical Trials 135

Drug Discovery World

DECEMBER 20, 2022

These are proteins critical for mounting potent anti-tumour responses and are used in immunotherapy to activate or enhance the body’s response. . Dr Moraga says he and his colleagues are looking forward to furthering the development of these new pH-selective cytokines and expect to enter the first clinical trials within a few years. .

Protein 52

Protein Life Science Engineer Clinical Trials 52

pharmaphorum

JANUARY 10, 2023

BioNTech said the acquisition is part of a strategy to accelerate its pipeline development and support R&D at scale, particularly in oncology, where it currently has 19 clinical-stage programmes and 22 ongoing clinical trials, headed by BNT122 for melanoma and colorectal cancer.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. protein-based biologics) and vaccine treatments. Cell-Based Immunotherapy vs. Immune Biologics.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. “Our minibinders sit on top of the spike protein like a tripod and block all three.

Antibody 52

Antibody Protein Engineer Manufacturing 52

XTalks

MAY 24, 2024

” XTALKS WEBINAR: AI-based Antibody Therapeutics Developability Assessment and Its Engineering Live and On-Demand: Friday, June 21, 2024, at 10am EDT (4pm CEST/EU-Central) Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

Drug Discovery World

JANUARY 21, 2024

It is enabling computational protein design for vaccine immunogen discovery, and high-throughput and high-definition assays for quicker and more comprehensive characterisation of vaccine candidates and vaccine-elicited immunity. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Protein 52

Protein Vaccination Vaccine Development 52

XTalks

JANUARY 8, 2024

The FDA’s endorsement stems from results obtained from the company’s Phase III NefIgArd clinical trial. This accumulation triggers inflammation and damages kidney tissues, leading to the leakage of blood and protein into the urine. IgAN, a rare kidney disorder, is marked by the accumulation of IgA deposits within the kidneys.

FDA Approval 64

FDA Approval Clinical Trials Clinical Trials Nurses 64

XTalks

AUGUST 8, 2022

The I-ReSToRE platform combines proprietary antibody engineering with MiroBio’s advanced receptor mapping database and visualization tool called Checkpoint Atlas. The acquisition of MiroBio is a testament to the best-in-class discovery engine and highly innovative pipeline they have built.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

Drug Discovery World

MARCH 22, 2023

The research team, including lead author David Mai, a Bioengineering graduate student in the School of Engineering and Applied Science, hypothesised that targeting the related, but independent Roquin-1 regulator at the same time could boost responses further. In some mice, it also led to overproduction of lymphocytes, causing toxicity.

Gene Editing 52

Gene Editing Gene Engineer Regulation 52

WCG Clinical

NOVEMBER 17, 2023

This change expanded the definition of HGT research to include research using nucleic acids that are able to replicate, be transcribed, translated into protein, and/or integrate into the host genome. Since then, however, certain genetic engineering technologies (e.g.,

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

XTalks

MAY 9, 2024

XTALKS CLINICAL EDGE: Issue 2 — Genmab’s Interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. Celebrating 25 years of innovation is a significant milestone.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Bioengineer

JULY 20, 2021

Surgical scars treated with a molecule called alphaCT1 showed a long-term improvement in appearance when compared to control scars, according to multicenter, controlled Phase II clinical trials – a finding that could help surgeons improve patient outcomes. to bring alphaCT1 to market. Original Source. https:/ / vtx.

Scientist 52

Scientist Engineer Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. The FDA’s endorsement of Sunlenca is backed by compelling clinical evidence, demonstrating its efficacy as a viable treatment option. In addition, Vir Biotechnology, Inc.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. SL-172154 entered clinical trials in mid-2020, following promising preclinical results.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Roots Analysis

DECEMBER 9, 2021

The anti-HER2 therapies target the HER2 receptor proteins present on the surface of tumor cells, inhibiting the HER2 receptors from receiving signals in order to terminate the cellular growth. These therapies can be used as a monotherapy or in combination with other therapeutic modalities, such as chemotherapy, surgery or radiation therapy.

Marketing 52

Marketing Development Gene Protein 52

XTalks

MARCH 10, 2023

It is caused by a mutation in the FXN gene , which is responsible for the production of the protein frataxin. Omaveloxolone Clinical Trials Skyclarys is an oral medication that contains omaveloxolone, an activator of the nuclear factor-erythroid 2 related factor 2 (Nrf2) pathway. Perlman in the same press release.

FDA Approval 52

FDA Approval Engineer Clinical Trials Clinical Trials 52

pharmaphorum

APRIL 8, 2022

The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year. Image by Lukas Bieri from Pixabay .

Drugs 105

Drugs Immune Response Licensing Licensing 105

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. Novavax expects to begin its pivotal Phase 3 clinical trial in the United States and Mexico by the end of November. and globally.”.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 9, 2023

T-cell activation not only causes the death of cancer cells through the release of special T-cell proteins which punch holes in their surface, but it also triggers the proliferation of killer T-cells at the tumour site (thereby increasing the ‘hotness’ of the tumour). RA: What kind of cancers could benefit from this treatment approach?

Antibody 64

Antibody Protein Development Engineer 64

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

Roots Analysis

DECEMBER 13, 2021

According to research study, 69% of participant were found to take part more likely in clinical trials, if they are able to provide self-collected sample (at-home blood collection). However, in recent years, the methods for blood collection are evolving at a rapid pace. Our Social Media Platform.

Engineer 52

Engineer Clinical Trials Clinical Trials Protein 52

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. pivotal Phase 3 trial update. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Bioengineer

JULY 23, 2021

Credit: Texas A&M Engineering. The team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station. “For the first time, we identified a crucial interaction between platelets and the tumor via their surface proteins,” Jain said. ” ###. Original Source.

Engineer 52

Engineer Gene Editing Clinical Trials Clinical Trials 52